Sacubitril/Valsartan in the Treatment of Heart Failure With Reduced Ejection Fraction Focusing on the Impact on the Quality of Life: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

Cureus · 2023 · PMC10714125 · PMID 38090453

Europe PMC DOI

hedged sentences

0.7600

closest p · 15.2× alpha

0.7600

boldest claim

The sentences

did not reach statistical significancep = 0.76not close (p > 0.1)

The interaction between NYHA class at randomization and the effect of the treatment on the major endpoint did not reach statistical significance (p = 0.76) nor for the effect of the drug on mortality from cardiovascular causes (p = 0.03, without multiple comparison adjustments).

also in 111,027 other papers

showed a trendno p-value reported

From the PARALLEL-HF study's randomization to the pre-specified time points of week 8 (LSM change from baseline for sacubitril/valsartan versus enalapril: 0.05 versus 2.59; p = 0.1854) and month 6 (2.22 versus 3.49; p = 0.5737), sacubitril/valsartan showed a trend to a lesser deterioration of KCCQ clinical summary score for HF symptoms and physical limitations [ 48 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.